Iconix Biosciences, a Mountain View, Calif. gene expression profiling provider, has received $4 million in seventh round of funding from a research and licensing pact with Eli Lilly & Co., according to VentureWire (sub required):

Through the agreement with Lilly, Iconix may raise an additional $2 million through the deal whereby Lilly has access to Iconix’s data set, DrugMatrix, to test for a drug’s toxicity mechanism.